RCBTB1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8NDN9 |
---|---|
Clone Names | 110617148 |
Gene ID | 55213 |
---|---|
Other Names | RCC1 and BTB domain-containing protein 1, Chronic lymphocytic leukemia deletion region gene 7 protein, CLL deletion region gene 7 protein, Regulator of chromosome condensation and BTB domain-containing protein 1, RCBTB1, CLLD7, E45 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | RCBTB1 |
---|---|
Synonyms | CLLD7, E4.5 |
Function | May be involved in cell cycle regulation by chromatin remodeling. |
Cellular Location | Nucleus. |
Tissue Location | Ubiquitously expressed (PubMed:11306461, PubMed:27486781). In the retina, present in the nerve fiber layer and to a lesser extent in the inner and outer plexiform layers (at protein level) (PubMed:27486781). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a protein with an N-terminal RCC1 domainand a C-terminal BTB (broad complex, tramtrack and bric-a-brac)domain. In rat, over-expression of this gene in vascular smoothmuscle cells induced cellular hypertrophy. In rat, the C-terminusof RCBTB1 interacts with the angiotensin II receptor-1A. In humans,this gene maps to a region of chromosome 13q that is frequentlydeleted in B-cell chronic lymphocytic leukemia and other lymphoidmalignancies.
References
Genuneit, J., et al. Clin. Exp. Allergy 39(12):1875-1888(2009)Guo, D.F., et al. J. Biol. Chem. 279(20):21109-21120(2004)Dunham, A., et al. Nature 428(6982):522-528(2004)Solomou, E.E., et al. Leuk. Lymphoma 44(9):1579-1585(2003)Mabuchi, H., et al. Cancer Res. 61(7):2870-2877(2001)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.